Ray Asghari
Overview
Explore the profile of Ray Asghari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang R, Adams D, Roncolato F, Asghari R, Descallar J, Pal A, et al.
Clin Genitourin Cancer
. 2024 May;
22(4):102116.
PMID: 38810324
Purpose: Adherence to active surveillance in patients with stage 1 testicular cancers may be influenced by factors affecting capacity and motivation to attend appointments. The aims of this study were...
2.
Shahnam A, Nindra U, McNamee N, Yoon R, Asghari R, Ng W, et al.
Gastrointest Tumors
. 2023 Oct;
10(1):19-28.
PMID: 37901653
Introduction: Treatment of oesophageal (OC), gastro-oesophageal junction (GOJ), and gastric cancer (GC) includes either neoadjuvant Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) for OC or GOJ or perioperative...
3.
Nindra U, Pal A, Lea V, Lim S, Wilkinson K, Asghari R, et al.
PLoS One
. 2023 Oct;
18(10):e0292087.
PMID: 37796807
Background: Next generation sequencing (NGS) is increasingly used in standard clinical practice to identify patients with potentially actionable mutations. Stratification of NGS mutation tiers is currently based on the European...
4.
Lim S, Chua W, Ng W, Ip E, Marques T, Tran N, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627212
Locally advanced rectal cancer (LARC) has traditionally been treated with trimodality therapy consisting of neoadjuvant radiation +/- chemotherapy, surgery, and adjuvant chemotherapy. There is currently a clinical need for biomarkers...
5.
Yoon R, Wilkinson K, Gabriel G, Kadaan N, Roberts T, Lim S, et al.
Asia Pac J Clin Oncol
. 2023 May;
20(1):63-70.
PMID: 37211922
Introduction: Fluoropyrimidine and oxaliplatin-based adjuvant chemotherapy delivered as 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX), or capecitabine and oxaliplatin (CAPOX) is the standard of care for resected stage III colon cancer. Without...
6.
McNamee N, Nindra U, Shahnam A, Yoon R, Asghari R, Ng W, et al.
J Gastrointest Oncol
. 2023 May;
14(2):494-503.
PMID: 37201072
Background: Neoadjuvant carboplatin and paclitaxel with radiotherapy (CROSS) and perioperative docetaxel, oxaliplatin, calcium folinate and fluorouracil (FLOT) are widely used for gastric (GC), gastro-oesophageal junction (GOJ) and oesophageal cancers (OC)....
7.
Thavaneswaran S, Chan W, Asghari R, Grady J, Deegan M, Jansen V, et al.
JCO Precis Oncol
. 2022 Dec;
6:e2200263.
PMID: 36455193
No abstract available.
8.
Lim S, Ip E, Ng W, Chua W, Asghari R, Roohullah A, et al.
Cancers (Basel)
. 2019 Aug;
11(9).
PMID: 31466306
There is limited data on health-related quality of life (HRQoL) in locally advanced rectal cancer. We assessed HRQoL before, during and after neoadjuvant chemoradiation, correlated this to corresponding clinician-reported adverse...
9.
Goel S, Liu J, Guo H, Barry W, Bell R, Murray B, et al.
JACC Heart Fail
. 2019 Aug;
7(9):795-804.
PMID: 31401102
Objectives: The aim of CATS (Cardiotoxicity of Adjuvant Trastuzumab Study) was to prospectively assess clinical, biochemical, and genomic predictors of trastuzumab-related cardiotoxicity (TRC). Background: Cardiac dysfunction is a common adverse...
10.
Khan S, Asghari R, Lin M
Intern Med J
. 2018 Jul;
48(7):885-886.
PMID: 29984506
No abstract available.